Back to Search
Start Over
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
- Source :
- Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
- Publication Year :
- 2023
- Publisher :
- Nature Portfolio, 2023.
-
Abstract
- In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation positive advanced biliary tract cancers.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 14
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.6b0c6dc798b14d37bd9664bd41aec7e1
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-023-36399-y